JP Morgan Chase
KROS icon

JP Morgan Chase’s Keros Therapeutics KROS Stock Holding History

JP Morgan Chase’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Sell
14,624
-23,056
-61% -$257K ﹤0.01% 5742
2026
Q1 		$402K Buy
37,680
+19,042
+102% +$294K ﹤0.01% 5152
2025
Q4 		$379K Sell
18,638
-153,303
-89% -$2.69M ﹤0.01% 5198
2025
Q3 		$2.72M Buy
171,941
+124,287
+261% +$1.84M ﹤0.01% 3847
2025
Q2 		$636K Sell
47,654
-2,552,803
-98% -$34.5M ﹤0.01% 4646
2025
Q1 		$26.5M Buy
2,600,457
+2,387,026
+1,118% +$27.7M ﹤0.01% 1700
2024
Q4 		$3.38M Buy
213,431
+182,314
+586% +$9.47M ﹤0.01% 3734
2024
Q3 		$1.81M Buy
31,117
+422
+1% +$20.8K ﹤0.01% 4078
2024
Q2 		$1.4M Sell
30,695
-24,715
-45% -$1.33M ﹤0.01% 4045
2024
Q1 		$3.67M Sell
55,410
-7,234
-12% -$429K ﹤0.01% 3357
2023
Q4 		$2.49M Buy
62,644
+9,575
+18% +$300K ﹤0.01% 3667
2023
Q3 		$1.69M Buy
53,069
+23,379
+79% +$873K ﹤0.01% 3672
2023
Q2 		$1.19M Buy
29,690
+6,270
+27% +$275K ﹤0.01% 3915
2023
Q1 		$1M Sell
23,420
-18,061
-44% -$912K ﹤0.01% 4049
2022
Q4 		$1.99M Buy
41,481
+23,710
+133% +$1.11M ﹤0.01% 3558
2022
Q3 		$669K Buy
17,771
+2,547
+17% +$88.3K ﹤0.01% 4272
2022
Q2 		$420K Sell
15,224
-22,304
-59% -$979K ﹤0.01% 4672
2022
Q1 		$2.04M Buy
37,528
+4,329
+13% +$222K ﹤0.01% 3736
2021
Q4 		$1.94M Buy
33,199
+22,697
+216% +$1.13M ﹤0.01% 3887
2021
Q3 		$415K Buy
10,502
+1,231
+13% +$43.8K ﹤0.01% 4836
2021
Q2 		$393K Buy
9,271
+2,882
+45% +$156K ﹤0.01% 4844
2021
Q1 		$393K Buy
6,389
+555
+10% +$35.2K ﹤0.01% 4827
2020
Q4 		$411K Buy
5,834
+3,237
+125% +$204K ﹤0.01% 4483
2020
Q3 		$102K Buy
2,597
+254
+11% +$10.1K ﹤0.01% 4682
2020
Q2 		$88K Buy
+2,343
New +$72.2K ﹤0.01% 4621

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

JP Morgan Chase's KROS Position: Q2 2026 in Review

JP Morgan Chase reduced its Keros Therapeutics (KROS) stake by 61% in Q2 2026, selling an estimated $257K and leaving 14,624 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #5742.

JP Morgan Chase first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $26.5M in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • JP Morgan Chase held 14,624 shares of Keros Therapeutics worth $160K as of Q2 2026.
  • JP Morgan Chase sold 23,056 Keros Therapeutics shares in Q2 2026, an estimated $257K.
  • Keros Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5742 holding.
  • JP Morgan Chase first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Keros Therapeutics position peaked at $26.5M in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.